Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Eckstein M, et al. Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528808
PD-L1 assessment in urothelial carcinoma: a practical approach.
Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T. Eckstein M, et al. Ann Transl Med. 2019 Nov;7(22):690. doi: 10.21037/atm.2019.10.24. Ann Transl Med. 2019. PMID: 31930091 Free PMC article. Review.
Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view.
Cimadamore A, Scarpelli M, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R. Cimadamore A, et al. Among authors: eckstein m. Expert Opin Biol Ther. 2020 Jun;20(6):539-544. doi: 10.1080/14712598.2020.1733965. Epub 2020 Feb 25. Expert Opin Biol Ther. 2020. PMID: 32081061 No abstract available.
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, Vögeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, Niegisch G, Gaisa NT; German Study Group of Bladder Cancer (DFBK e.V.). Morsch R, et al. Among authors: eckstein m. BMC Cancer. 2020 Mar 18;20(1):230. doi: 10.1186/s12885-020-06727-2. BMC Cancer. 2020. PMID: 32188412 Free PMC article.
PD1/PD-L1 Axis in Uro-oncology.
Junker K, Eckstein M, Fiorentino M, Montironi R. Junker K, et al. Among authors: eckstein m. Curr Drug Targets. 2020;21(13):1293-1300. doi: 10.2174/1389450121666200326123700. Curr Drug Targets. 2020. PMID: 32213156 Review.
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, Gostian AO, Frey B, Gaipl US, Zhou JG, Fietkau R, Hecht M. Schweizer C, et al. Among authors: eckstein m. Eur J Cancer. 2020 Nov;140:55-62. doi: 10.1016/j.ejca.2020.09.001. Epub 2020 Oct 9. Eur J Cancer. 2020. PMID: 33045663 Clinical Trial.
716 results